Clinical Trial Update: Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin [Phase 3]

View source ↗

Summary

Phase 3 trial comparing capsules of lyophilised faecal microbiota to fidaxomicin for primary or recurrent Clostridioides difficile infection has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Fidaxomicin (fidaxomicin)
• Lyophilised Faecal Microbiota Capsules

Snippet

Sponsor: Mikrobiomik Healthcare Company S.L. | Conditions: Recurrent Clostridium Difficile Infection, Primary Clostridium Difficile Infection | Phase 3 | Status: COMPLETED | Results posted: 2025-03-25